

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PAT1749363

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	GALVANIZE THERAPEUTICS, INC.	01/10/2025
<b>RECEIVING PARTY DATA</b>		
<b>Company Name:</b>	SYMBIOTIC CAPITAL AGENCY LLC	
<b>Street Address:</b>	10100 Santa Monica Blvd.	
<b>City:</b>	Los Angeles	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	90067	
<b>PROPERTY NUMBERS Total: 78</b>		
<b>Property Type</b>	<b>Number</b>	
Application Number:	63061091	
Application Number:	63061114	
Application Number:	63209335	
Application Number:	18163082	
Application Number:	18534287	
Application Number:	63077022	
Application Number:	17587844	
Application Number:	62355164	
Application Number:	62489753	
Application Number:	17824720	
Application Number:	17941815	
Application Number:	18645220	
Application Number:	62693622	
Application Number:	18423043	
Application Number:	62835846	
Application Number:	17502640	
Application Number:	63189358	
Application Number:	17746361	
Application Number:	63480440	
Application Number:	63502877	

<b>Property Type</b>	<b>Number</b>
Application Number:	18416505
Application Number:	62874605
Application Number:	17575500
Application Number:	62902004
Application Number:	63076536
Application Number:	63241241
Application Number:	62994620
Application Number:	17212833
Application Number:	63007233
Application Number:	63078784
Application Number:	17962142
Application Number:	63166145
Application Number:	18472535
Application Number:	63178174
Application Number:	63336197
Application Number:	63209319
Application Number:	18533642
Application Number:	63246239
Application Number:	63322319
Application Number:	63351562
Application Number:	63480468
Application Number:	63488304
Application Number:	18416809
Application Number:	63517342
Application Number:	18792495
Application Number:	63290529
Application Number:	63341937
Application Number:	18945229
Application Number:	63491025
Application Number:	63578134
Application Number:	63597639
Application Number:	63659030
Application Number:	63645699
Patent Number:	11638819
Patent Number:	11369433
Patent Number:	10702337
Patent Number:	10939958
Patent Number:	11471208

Property Type	Number
Patent Number:	11324543
Patent Number:	11547851
Patent Number:	11938317
PCT Number:	US2144469
PCT Number:	US2215217
PCT Number:	US2130911
PCT Number:	US2360897
PCT Number:	US1739527
PCT Number:	US1867501
PCT Number:	US1867504
PCT Number:	US2028844
PCT Number:	US2042260
PCT Number:	US2126221
PCT Number:	US2221888
PCT Number:	US2320282
PCT Number:	US2232981
PCT Number:	US2244021
PCT Number:	US2322109
PCT Number:	US2420309
PCT Number:	US2443295

**CORRESPONDENCE DATA**

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 8004945225

**Email:** ipteam@cogencyglobal.com

**Correspondent Name:** Jay daSilva

**Address Line 1:** 1025 Connecticut Avenue NW

**Address Line 2:** Suite 712

**Address Line 4:** Washington, DISTRICT OF COLUMBIA 20036

<b>ATTORNEY DOCKET NUMBER:</b>	2622928 JD PAT
<b>NAME OF SUBMITTER:</b>	Jay daSilva
<b>SIGNATURE:</b>	Jay daSilva
<b>DATE SIGNED:</b>	01/13/2025

**Total Attachments: 9**

source=Galvanize Therapeutics - Intellectual Property Security Agreement#page1.tiff  
source=Galvanize Therapeutics - Intellectual Property Security Agreement#page2.tiff  
source=Galvanize Therapeutics - Intellectual Property Security Agreement#page3.tiff  
source=Galvanize Therapeutics - Intellectual Property Security Agreement#page4.tiff

source=Galvanize Therapeutics - Intellectual Property Security Agreement#page5.tiff  
source=Galvanize Therapeutics - Intellectual Property Security Agreement#page6.tiff  
source=Galvanize Therapeutics - Intellectual Property Security Agreement#page7.tiff  
source=Galvanize Therapeutics - Intellectual Property Security Agreement#page8.tiff  
source=Galvanize Therapeutics - Intellectual Property Security Agreement#page9.tiff

**INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “**Agreement**”) is entered into as of January 10, 2024, between **GALVANIZE THERAPEUTICS, INC.**, a Delaware corporation (“**Grantor**”), and **SYMBIOTIC CAPITAL AGENCY LLC**, as collateral agent (in such capacity, together with its successors and assigns, “**Collateral Agent**”).

RECITALS

A. Grantor, each other Person party to the Loan Agreement as a borrower from time to time (collectively, “**Borrowers**”, and each, a “**Borrower**”), each other Person party to the Loan Agreement as a guarantor from time to time (collectively, “**Guarantors**” and each, a “**Guarantor**”, and together with Borrowers, collectively, “**Loan Parties**”, and each, a “**Loan Party**”), the lenders from time to time party to the Loan Agreement (collectively, “**Lenders**” and each, a “**Lender**”), and **SYMBIOTIC CAPITAL AGENCY LLC**, as administrative agent (in such capacity, together with its successors and assigns, “**Administrative Agent**”) and Collateral Agent, as collateral agent, are entering into a Loan and Security Agreement as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “**Loan Agreement**”). Defined terms used herein without definition shall have the meanings set forth in the Loan Agreement.

B. The Obligations are secured by the Collateral, as defined in the Loan Agreement, including without limitation, all of Grantor’s Intellectual Property (other than Excluded Assets).

C. Grantor’s execution and delivery of this Agreement is a condition to the effectiveness of the Loan Agreement.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, Grantor and Collateral Agent hereby agree:

1. To secure the Obligations, Grantor grants Collateral Agent a security interest in all of Grantor’s right, title and interest in its Intellectual Property; provided that no security interest is granted in any Excluded Asset. Grantor hereby confirms that the attached schedules of Grantor’s copyright, patent and trademark applications and registrations, which are registered or filed with the United States Patent and Trademark Office or the United States Copyright Office, as applicable, attached as Exhibit A hereto, are complete and accurate as of the date hereof.

2. This Agreement shall be exclusively (without regard to any rules or principles relating to conflicts of laws that would result in the application of the laws of any other jurisdiction) governed by, enforced and construed in accordance with the laws of the State of New York; provided that Section 5-1401 of the New York General Obligations Law shall apply.

3. This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. The words “execution,” “signed,” “signature” and words of like import shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity and enforceability as a manually executed signature or the use of a paper-based recordkeeping systems, as the case may be, to the extent and as provided for in any applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act. Delivery of an executed counterpart of a signature page to this Agreement by electronic means including by email delivery of a “.pdf” format data file shall be effective as delivery of an original executed counterpart of this Agreement.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT]

IN WITNESS WHEREOF, the undersigned have duly executed this Intellectual Property Security Agreement as of the first date written above.

Address of Grantor:

3200 Bridge Pkwy  
Redwood City, CA 94065  
Attn: Steve Anheier  
Email: sanheier@galvanizetx.com

GRANTOR:

GALVANIZE THERAPEUTICS, INC.

DocuSigned by:  
  
By \_\_\_\_\_  
Name: Jonathan Waldstreicher  
Title: Chief Executive Officer, President and Secretary

Address of Collateral Agent:

10100 Santa Monica Blvd.  
Los Angeles, CA 90067  
Attn: Himani Bhalla  
Email: legal@symbcap.com

COLLATERAL AGENT:

SYMBIOTIC CAPITAL AGENCY LLC

With copies (not constituting notice) to:

Morrison & Foerster LLP  
425 Market Street  
San Francisco, CA 94105  
Attn: Victor Liang  
Email: VLiang@mfo.com

By: \_\_\_\_\_  
Name: Himani Bhalla  
Title: Senior Managing Director

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT]

IN WITNESS WHEREOF, the undersigned have duly executed this Intellectual Property Security Agreement as of the first date written above.

Address of Grantor:

3200 Bridge Pkwy  
Redwood City, CA 94065  
Attn: \_\_\_\_\_  
Email: \_\_\_\_\_

GRANTOR:

GALVANIZE THERAPEUTICS, INC.


By \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

Address of Collateral Agent:

10100 Santa Monica Blvd.  
Los Angeles, CA 90067  
Attn: Himani Bhalla  
Email: legal@symbcap.com

COLLATERAL AGENT:

SYMBIOTIC CAPITAL AGENCY LLC



With copies (not constituting notice) to:

Morrison & Foerster LLP  
425 Market Street  
San Francisco, CA 94105  
Attn: Victor Liang  
Email: VLiang@mof.com

By: \_\_\_\_\_  
Name: Himani Bhalla  
Title: Senior Managing Director

EXHIBIT A  
PATENTS

<b>Company (Owner of Patent)</b>	<b>Patent / Patent Application</b>	<b>Patent No. / Application No.</b>	<b>Issue Date / Application Date</b>
Galvanize Therapeutics, Inc.	PULSED ELECTRIC FIELDS IN THE EYE ENHANCED TRANSFER WITH PULSED ELECTRIC FIELDS	63/061,091	
Galvanize Therapeutics, Inc.	INDUCED EXTRAVASATION BY ENERGY DELIVERY TO TISSUE	63/061,114	
Galvanize Therapeutics, Inc.	PULSED ELECTRIC FIELD TRANSFER OF MOLECULES TO CELLS WHILE IN THE BODY	63/209,335	
Galvanize Therapeutics, Inc.	PULSED ELECTRIC FIELD TRANSFER OF MOLECULES TO CELLS WHILE IN THE BODY	18/163,082	
Galvanize Therapeutics, Inc.	INDUCED EXTRAVASATION BY ENERGY DELIVERY TO TISSUE	18/534,287	
Galvanize Therapeutics, Inc.	PULSED ELECTRIC FIELD TRANSFER OF MOLECULES TO CELLS WHILE IN THE BODY	PCT/US21/44469	
Galvanize Therapeutics, Inc.	INDUCED EXTRAVASATION BY ENERGY DELIVERY TO TISSUE	PCT/US22/15217	
Galvanize Therapeutics, Inc.	SIGNAL GENERATORS FOR USE WITH TISSUE MODIFICATION SYSTEMS	63/077,022	9/11/2020
Galvanize Therapeutics, Inc.	SIGNAL GENERATORS FOR USE WITH TISSUE MODIFICATION SYSTEMS	11,638,819	5/2/2023
Galvanize Therapeutics, Inc.	SIGNAL GENERATORS FOR USE WITH TISSUE MODIFICATION SYSTEMS	PCT/US2021/030911	5/5/2021
Galvanize Therapeutics, Inc.	TISSUE MODIFICATION SYSTEMS AND METHODS AND SIGNAL GENERATORS FOR USE THEREWITH	17/587,844	1/28/2022
Galvanize Therapeutics, Inc.	TISSUE MODIFICATION SYSTEMS AND METHODS AND SIGNAL GENERATORS FOR USE THEREWITH	PCT/US2023/060897	1/19/2023
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF PULMONARY DISORDERS	62/355,164	6/27/2016
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF PULMONARY DISORDERS	62/489,753	4/25/2017



Company (Owner of Patent)	Patent / Patent Application	Patent No. / Application No.	Issue Date / Application Date
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF PULMONARY DISORDERS	11,369,433	6/28/2022
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF PULMONARY DISORDERS	10,702,337	7/7/2020
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF PULMONARY DISORDERS	10,939,958	3/9/2021
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF PULMONARY DISORDERS	17/824,720	5/25/2022
Galvanize Therapeutics, Inc.	GENERATOR AND A CATHETER WITH AN ELECTRODE AND A METHOD FOR TREATING A LUNG PASSAGEWAY	PCT/US2017/039527	6/27/2017
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF DISEASE STATES AND DISORDERS	11,471,208	10/18/2022
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF DISEASE STATES AND DISORDERS	11,324,543	5/10/2022
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF DISEASE STATES AND DISORDERS	17/941,815	9/9/2022
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF DISEASE STATES AND DISORDERS	18/645,220	4/24/2024
Galvanize Therapeutics, Inc.	METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF PULMONARY DISORDERS	PCT/US2018/067501	12/26/2018
Galvanize Therapeutics, Inc.	OPTIMIZATION OF ENERGY DELIVERY FOR VARIOUS APPLICATIONS	62/693,622	7/3/2018
Galvanize Therapeutics, Inc.	OPTIMIZATION OF ENERGY DELIVERY FOR VARIOUS APPLICATIONS	11,547,851	1/10/2023
Galvanize Therapeutics, Inc.	OPTIMIZATION OF ENERGY DELIVERY FOR VARIOUS APPLICATIONS	11,938,317	3/26/2024

Company (Owner of Patent)	Patent / Patent Application	Patent No. / Application No.	Issue Date / Application Date
Galvanize Therapeutics, Inc.	OPTIMIZATION OF ENERGY DELIVERY FOR VARIOUS APPLICATIONS	18/423,043	1/25/2024
Galvanize Therapeutics, Inc.	OPTIMIZATION OF ENERGY DELIVERY FOR VARIOUS APPLICATIONS	PCT/US2018/067504	12/26/2018
Galvanize Therapeutics, Inc.	TISSUE TREATMENT FROM WITHIN LUMINAL STRUCTURES	62/835,846	4/18/2019
Galvanize Therapeutics, Inc.	DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF ABNORMAL TISSUE	17/502,640	10/15/2021
Galvanize Therapeutics, Inc.	APPLYING PULSED ELECTRIC FIELDS IN THE TREATMENT OF NEURAL DISORDERS	63/189,358	5/17/2021
Galvanize Therapeutics, Inc.	APPLYING PULSED ELECTRIC FIELDS IN THE TREATMENT OF NEURAL DISORDERS	17/746,361	5/17/2022
Galvanize Therapeutics, Inc.	COMBINATION THERAPY WITH PULSED ELECTRIC FIELDS	63/480,440	1/18/2023
Galvanize Therapeutics, Inc.	COMBINATION THERAPY WITH PULSED ELECTRIC FIELDS	63/502,877	5/17/2023
Galvanize Therapeutics, Inc.	APPLYING PULSED ELECTRIC FIELDS IN THE TREATMENT OF NEURAL DISORDERS	18/416,505	1/18/2024
Galvanize Therapeutics, Inc.	DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF ABNORMAL TISSUE	PCT/US2020/028844	4/17/2020
Galvanize Therapeutics, Inc.	TREATMENT OF THE REPRODUCTIVE TRACT WITH PULSED ELECTRIC FIELDS	62/874,605	7/16/2019
Galvanize Therapeutics, Inc.	TREATMENT OF THE REPRODUCTIVE TRACT WITH PULSED ELECTRIC FIELDS	17/575,500	1/13/2022
Galvanize Therapeutics, Inc.	TREATMENT OF THE REPRODUCTIVE TRACT WITH PULSED ELECTRIC FIELDS	PCT/US2020/042260	7/16/2020
Galvanize Therapeutics, Inc.	HIGH VOLTAGE BIPHASIC WAVEFORM GENERATOR	62/902,004	9/18/2019
Galvanize Therapeutics, Inc.	HIGH VOLTAGE BIPHASIC WAVEFORM GENERATOR	63/076,536	9/10/2020
Galvanize Therapeutics, Inc.	HIGH VOLTAGE BIPHASIC WAVEFORM GENERATOR	63/241,241	9/7/2021
Galvanize Therapeutics, Inc.	IMMUNOSTIMULATION IN THE TREATMENT OF VIRAL INFECTION	62/994,620	3/25/2020
Galvanize Therapeutics, Inc.	IMMUNOSTIMULATION IN THE TREATMENT OF VIRAL INFECTION	17/212,833	3/25/2021

Company (Owner of Patent)	Patent / Patent Application	Patent No. / Application No.	Issue Date / Application Date
Galvanize Therapeutics, Inc.	PULSED ELECTRIC FIELD WAVEFORM MANIPULATION AND USE	63/007,233	4/8/2020
Galvanize Therapeutics, Inc.	PULSED ELECTRIC FIELD WAVEFORM MANIPULATION AND USE	63/078,784	9/15/2020
Galvanize Therapeutics, Inc.	PULSED ELECTRIC FIELD WAVEFORM MANIPULATION AND USE	17/962,142	10/7/2022
Galvanize Therapeutics, Inc.	PULSED ELECTRIC FIELD WAVEFORM MANIPULATION AND USE	PCT/US2021/026221	4/7/2021
Galvanize Therapeutics, Inc.	MULTI-ELECTRODE SYSTEM AND METHOD FOR DEDUCING TREATMENT EFFECT OUTCOMES	63/166,145	3/25/2021
Galvanize Therapeutics, Inc.	MULTI-ELECTRODE SYSTEM AND METHOD FOR DEDUCING TREATMENT EFFECT OUTCOMES	18/472,535	9/22/2023
Galvanize Therapeutics, Inc.	MULTI-ELECTRODE SYSTEM AND METHOD FOR DEDUCING TREATMENT EFFECT OUTCOMES	PCT/US2022/021888	3/25/2022
Galvanize Therapeutics, Inc.	LESION OPTIMIZATION IN THE USE OF PULSED ELECTRIC FIELDS	63/178,174	4/22/2021
Galvanize Therapeutics, Inc.	LESION OPTIMIZATION IN THE USE OF PULSED ELECTRIC FIELDS	63/336,197	4/28/2022
Galvanize Therapeutics, Inc.	LESION OPTIMIZATION IN THE USE OF PULSED ELECTRIC FIELDS	PCT/US2023/020282	4/27/2023
Galvanize Therapeutics, Inc.	APPLYING PULSED ELECTRIC FIELDS IN THE TREATMENT OF THE VASCULATURE	63/209,319	6/10/2021
Galvanize Therapeutics, Inc.	APPLYING PULSED ELECTRIC FIELDS IN THE TREATMENT OF THE VASCULATURE	18/533,642	12/8/2023
Galvanize Therapeutics, Inc.	APPLYING PULSED ELECTRIC FIELDS IN THE TREATMENT OF THE VASCULATURE	PCT/US2022/032981	6/10/2022
Galvanize Therapeutics, Inc.	COMBINATORIAL PULSED ELECTRIC FIELD THERAPY	63/246,239	9/20/2021
Galvanize Therapeutics, Inc.	CONTROLLED LESION AND IMMUNE RESPONSE	63/322,319	3/22/2022
Galvanize Therapeutics, Inc.	CONTROLLED LESION AND IMMUNE RESPONSE	63/351,562	6/13/2022
Galvanize Therapeutics, Inc.	DIFFERENTIAL IMMUNE RESPONSE OF PULSED ELECTRIC FIELDS	63/480,468	1/18/2023

<b>Company</b> <i>(Owner of Patent)</i>	<b>Patent / Patent Application</b>	<b>Patent No. / Application No.</b>	<b>Issue Date / Application Date</b>
Galvanize Therapeutics, Inc.	DIFFERENTIAL IMMUNE RESPONSE OF PULSED ELECTRIC FIELDS	63/488,304	3/3/2023
Galvanize Therapeutics, Inc.	CONTROLLED LESION AND IMMUNE RESPONSE TO PULSED ELECTRIC FIELD THERAPY	18/416,809	1/18/2024
Galvanize Therapeutics, Inc.	IMMUNE MODULATION BY PULSED ELECTRIC FIELDS	63/517,342	8/2/2023
Galvanize Therapeutics, Inc.	CONTROLLED LESION AND IMMUNE RESPONSE TO PULSED ELECTRIC FIELD THERAPY	18/792,495	8/1/2024
Galvanize Therapeutics, Inc.	CONTROLLED LESION AND IMMUNE RESPONSE TO PULSED ELECTRIC FIELD THERAPY	PCT/US2022/044021	9/19/2022
Galvanize Therapeutics, Inc.	LOCAL TREATMENT WITH PULSED ELECTRIC FIELDS GENERATES A TUMOR SPECIFIC RESPONSE	63/290,529	12/16/2021
Galvanize Therapeutics, Inc.	DEVICES, SYSTEMS AND METHODS FOR TREATMENT OF LUNG AIRWAYS	63/341,937	5/13/2022
Galvanize Therapeutics, Inc.	DEVICES, SYSTEMS AND METHODS FOR TREATMENT OF LUNG AIRWAYS	18/945,229	11/12/2024
Galvanize Therapeutics, Inc.	DEVICES, SYSTEMS AND METHODS FOR TREATMENT OF LUNG AIRWAYS	PCT/US2023/022109	5/12/2023
Galvanize Therapeutics, Inc.	PULSED ELECTRIC FIELD ENERGY DELIVERY TIMING OPTIMIZATION	63/491,025	3/17/2023
Galvanize Therapeutics, Inc.	PULSED ELECTRIC FIELD ENERGY DELIVERY TIMING OPTIMIZATION	PCT/US2024/020309	3/15/2024
Galvanize Therapeutics, Inc.	ANTIBODY MODULATION BY PULSED ELECTRIC FIELDS	63/578,134	8/22/2023
Galvanize Therapeutics, Inc.	ANTIBODY QUANTIFICATION	63/597,639	11/9/2023
Galvanize Therapeutics, Inc.	ANTIBODY MODULATION BY PULSED ELECTRIC FIELDS	PCT/US2024/043295	8/21/2024
Galvanize Therapeutics, Inc.	ADVANCED BIPHASIC PULSED ELECTRIC FIELDS	63/659030	3/22/2024
Galvanize Therapeutics, Inc.	MUCUS DISIMPACTION OF THE LUNG	63/645699	5/10/2024

TRADEMARKS

<b>Company</b> <i>(Owner of Trademark)</i>	<b>Trademark / Trademark Application</b>	<b>Trademark No. / Application No.</b>	<b>Issue Date / Application Date</b>
Galvanize Therapeutics, Inc.	GALA THERAPEUTICS	5,875,289	10/1/2019
Galvanize Therapeutics, Inc.	RHEOX	6,234,255	12/29/2020
Galvanize Therapeutics, Inc.	GALVANIZE THERAPEUTICS	7,146,113	8/22/2023
Galvanize Therapeutics, Inc.	ALTYA	7,388,349	5/14/2024
Galvanize Therapeutics, Inc.	GALVANIZE	98/082,782	7/13/2023

COPYRIGHTS

<b>Company</b> <i>(Owner of Copyright)</i>	<b>Copyrights / Copyright Application</b>	<b>Copyright No. / Application No.</b>	<b>Issue Date / Application Date</b>
None.			